Identification of Licopyranocoumarin and Glycyrurol from Herbal Medicines as Neuroprotective Compounds for Parkinson's Disease.	Fujimaki T, Saiki S, Tashiro E, Yamada D, Kitagawa M, Hattori N, Imoto M.	PLoS ONE 2014; 9: e100395
Modeling human neurological disorders with induced pluripotent stem cells.	Imaizumi Y, Okano H	J Neurochem. 2014; 129:388-399
iPS Cell Technologies: Significance and Applications to CNS Regeneration and Disease Research.	Okano H and Yamanaka S	Mol Brain. 2014; 7:22
Neural Substrates of Cognitive Subtypes in Parkinson's Disease: A 3-Year Longitudinal Study	Shoji Y, Nishio Y, Baba T, Uchiyama M, Yokoi K, Ishioka T, Hosokai Y, Hirayama K, Fukuda H, Aoki M, Hasegawa T, Takeda A, Mori E.	PLoS One 2014; 9(10), e110547.
VPS35 dysfunction impairs lysosomal degradation of -synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease.	Miura E, Hasegawa T, Konno M, Suzuki M, Sugeno N, Fujikake N, Geisler S, Tabuchi M, Oshima R, Kikuchi A, Baba T, Wada K, Nagai Y, Takeda A, Aoki M.	Neurobiol. Dis. 2014; 71:1-13.
Lys-63-linked Ubiquitination by E3 Ubiquitin Ligase Nedd4-1 Facilitates Endosomal Sequestration of Internalized -Synuclein.	Sugeno N, Hasegawa T, Tanaka N, Fukuda M, Wakabayashi K, Oshima R, Konno M, Miura E, Kikuchi A, Baba T, Anan T, Nakao M, Geisler S, Aoki M, Takeda A.	J Biol. Chem. 2014; 289:18137-51.

CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study.	Funayama M, Ohe K, Amo T, Furuya N, Yamaguchi J, Saiki S, Li Y, Ogaki K, Ando M, Yoshino H, Tomiyama H, Nishioka K, Hasegawa K, Saiki H, Satake W, Mogushi K, Sasaki R, Kokubo Y, Kuzuhara S, Toda T, Mizuno Y, Uchiyama Y, Ohno K,　Hattori N.	Lancet Neurol 2015; 3:274-282
Detailed analysis of mitochondrial respiratory chain defects caused by loss of PINK1.	Amo T, Saiki S, Sawayama T, Sato S,　Hattori N.	Neurosci Lett 2014; 580C:37-40
Identification of licopyranocoumarin and glycyrurol from herbal medicines as neuroprotective compounds for Parkinson's disease.	Fujimaki T, Saiki S, Tashiro E, Yamada D, Kitagawa M,　Hattori N, Imoto M.	PLOS ONE 2014; 9:e100395
The promises of stem cells: stem cell therapy for movement disorders.	Mochizuki H, Choong CJ, Yasuda T.	Parkinsonism Relat Disord. 2014 Suppl 1: S128-131.
Advance in PD research explored a new field on ubiquitin biology.	Yamakado H	Mov Disord. 2014; 10:1243.

Genetic Epidemiology Of Parkinson's Disease (GEO-PD) Consortium. The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants	Heckman MG, Elbaz A, Soto-Ortolaza AI, Serie DJ, Aasly JO, Annesi G, Auburger G, Bacon JA, Boczarska-Jedynak M, Bozi M, Brighina L, Chartier-Harlin MC, Dardiotis E, Destée A, Ferrarese C, Ferraris A, Fiske B, Gispert S, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Jasinska-Myga B, Jeon BS, Kim YJ, Klein C, Kruger R, Kyratzi E, Lin CH, Lohmann K, Loriot MA, Lynch T, Mellick GD, Mutez E, Opala G, Park SS, Petrucci S, Quattrone A, Sharma M, Silburn PA, Sohn YH, Stefanis L, Tadic V, Tomiyama H, Uitti RJ, Valente EM, Vassilatis DK, Vilariño-Güell C, White LR, Wirdefeldt K, Wszolek ZK, Wu RM, Xiromerisiou G, Maraganore DM, Farrer MJ, Ross OA	Neurobiol Aging. 2014; 35:266.e5-14.
The role of Pak-interacting exchange factor-phosphorylation at serines 340 and 583 by PKC in dopamine release.	Shirafuji T, Ueyama T, Yoshino K, Takahashi H, Adachi N, Ago Y, Koda K, Nashida T, Hiramatsu N, Matsuda T, Toda T, Sakai N, Saito N.	J Neurosci. 2014; 34:9268-9280.
Viable neuronopathic Gaucher disease model in medaka (Oryzias latipes) displays axonal accumulation of alpha-synuclein.	Uemura N, Koike M, Ansai S, Kinoshita M, Ishikawa-Fujiwara T, Matsui H, Naruse K, Sakamoto N, Uchiyama Y, Todo T, Takeda S, Yamakado H, Takahashi R	PLoS Genet., in press.